{"id":210052,"date":"2017-02-22T00:50:40","date_gmt":"2017-02-22T05:50:40","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/two-pore-guys-to-present-at-point-of-care-diagnostics-symposium-at-the-molecular-medicine-tri-conference-yahoo-finance.php"},"modified":"2017-02-22T00:50:40","modified_gmt":"2017-02-22T05:50:40","slug":"two-pore-guys-to-present-at-point-of-care-diagnostics-symposium-at-the-molecular-medicine-tri-conference-yahoo-finance","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/two-pore-guys-to-present-at-point-of-care-diagnostics-symposium-at-the-molecular-medicine-tri-conference-yahoo-finance.php","title":{"rendered":"Two Pore Guys to Present at Point-of-Care Diagnostics Symposium at the Molecular Medicine Tri-Conference &#8211; Yahoo Finance"},"content":{"rendered":"<p><p>    SANTA CRUZ, Calif.--(BUSINESS WIRE)--  <\/p>\n<p>    Two Pore Guys, Inc., (2PG) today announced the company will    showcase its sample-in\/results-out molecular diagnostic    platform at the Point-of-Care Diagnostics symposium, part of    the Molecular Medicine Tri-Conference in San Francisco, on    February 23rd at the Moscone South Convention    Center.  <\/p>\n<p>    The symposium is comprised of both developers and end-users of    point of care (PoC) technologies, who will examine barriers to    entry and proposed solutions for this critical marketplace. CEO    Dan Heller and CSO Trevor Morin will discuss and demonstrate    2PGs technology in a presentation titled, Handheld, Single    Molecule Sensitive Diagnostic Platform, taking place from    12:40-1:15 p.m. PT in room 305.  <\/p>\n<p>    Multiple barriers to entry have historically limited the    commercial success of PoC diagnostics, such as rapid turnaround    time, off-grid power sources, clinical sensitivity, and a broad    menu of diagnostic tests. 2PGs battery operated, hand-held    device has single-molecule sensitivity and can measure targets    ranging from small molecules and proteins, to DNA or RNA,    including the presence of specific genes and mutations from    bacteria, viruses, people, animals, and any other life form.    The companys novel business model allows third-parties to    develop assays for its platform. Large diagnostic companies can    even adapt reagents already used in reference lab systems,    allowing for a broad menu of tests to be available for a PoC    market.  <\/p>\n<p>    Heller commented: Molecular diagnostics is the gold standard    for confirmatory diagnosis of infectious diseases, cancer, and    other critical conditions, but providing PoC technologies that    satisfy clinical sensitivity levels and can also be used    outside of labs at very low price points has been challenging.    Until now, no PoC solution has achieved single-molecule    sensitivity at a price point that can attain broad market    adoption, while also addressing multiple barriers to entry. We    believe our solution for the PoC market will open many exciting    opportunities for developers and end-users alike.  <\/p>\n<p>    2PG first formally introduced its platform last month when it    announced a collaboration with UCSF to use its hand-held device    to detect cell-free tumor DNA from blood and urine samples from    cancer patients. The company also presented its platform in    January at both the BioWeekSF series of conferences and at the    Precision Medicine World Conference in Silicon Valley, where it    won the prestigious Most Promising Company award.  <\/p>\n<p>    About Two Pore Guys  <\/p>\n<p>    Two Pore Guys (2PG) develops single-molecule sensing    technologies that employ solid-state nanopores and biochemical    reagents to create a versatile sample-in\/results-out detection    platform. 2PGs first product is a handheld device that can use    reagents from existing molecular or analyte diagnostic assays    and provide accuracy and sensitivity rivaling sophisticated    laboratory equipment. The battery-operated device is ideal for    point-of-use applications. The easy-to-use platform is designed    to sync with a smartphone or computer for further analysis and    data sharing, including integrationwith electronic health    records. Founded in 2011, the company is based in Santa Cruz,    Calif. More information, including videos demonstrating the    device, is available at twoporeguys.com.  <\/p>\n<p>    View source version on    businesswire.com: <a href=\"http:\/\/www.businesswire.com\/news\/home\/20170221005444\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/news\/home\/20170221005444\/en\/<\/a>  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continued here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/two-pore-guys-present-point-123000879.html\" title=\"Two Pore Guys to Present at Point-of-Care Diagnostics Symposium at the Molecular Medicine Tri-Conference - Yahoo Finance\">Two Pore Guys to Present at Point-of-Care Diagnostics Symposium at the Molecular Medicine Tri-Conference - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SANTA CRUZ, Calif.--(BUSINESS WIRE)-- Two Pore Guys, Inc., (2PG) today announced the company will showcase its sample-in\/results-out molecular diagnostic platform at the Point-of-Care Diagnostics symposium, part of the Molecular Medicine Tri-Conference in San Francisco, on February 23rd at the Moscone South Convention Center. The symposium is comprised of both developers and end-users of point of care (PoC) technologies, who will examine barriers to entry and proposed solutions for this critical marketplace <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/two-pore-guys-to-present-at-point-of-care-diagnostics-symposium-at-the-molecular-medicine-tri-conference-yahoo-finance.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-210052","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/210052"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=210052"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/210052\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=210052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=210052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=210052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}